complet
chapter
reader
understand
indic
transfus
variou
blood
productsth
current
outcom
data
regard
red
blood
cell
transfus
critic
ill
populationth
indic
irradi
filter
andor
leukoreduc
blood
productsth
type
transfus
reaction
treatmentth
risk
associ
blood
product
transfusionsth
complex
transfus
therapi
special
patient
popul
patient
pediatr
intens
care
unit
picu
frequent
receiv
transfus
blood
product
therapi
often
benefici
associ
signific
yet
often
overlook
risk
clinic
guidelin
blood
product
transfus
must
well
defin
order
prevent
misus
limit
resourc
import
intensivist
thorough
understand
indic
specif
blood
product
transfus
need
particular
patient
popul
common
indic
rbc
transfus
reduc
physiolog
reserv
sinc
anemia
decreas
oxygen
carri
capac
blood
therebi
oxygen
deliveri
tissu
augment
oxygen
deliveri
rbc
transfus
appear
appropri
goal
rbc
transfus
maintain
adequ
tissu
oxygen
deliveri
oxygen
deliveri
product
cardiac
output
co
arteri
oxygen
content
arteri
oxygen
content
function
hemoglobin
satur
hemoglobin
concentr
amount
oxygen
dissolv
arteri
blood
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
text
text
mlmin
text
cao
text
mldl
time
text
co
lmin
time
text
dll
end
document
goal
rbc
transfus
maintain
adequ
tissu
oxygen
deliveri
oxygen
deliveri
product
cardiac
output
co
arteri
oxygen
content
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
text
cao
text
mldl
mlg
time
text
hgb
text
gdl
time
text
sao
text
mldlmm
hg
time
text
pao
text
mm
hg
end
document
optim
red
blood
cell
concentr
allow
greatest
oxygen
deliveri
lowest
energi
cost
higher
rbc
concentr
increas
blood
viscos
inhibit
microvascular
perfus
lower
rbc
concentr
decreas
oxygen
carri
capac
signific
blood
loss
result
hypovolemia
anemia
acut
uncompens
anemia
caus
tissu
hypoxia
result
reduc
oxygencarri
capac
also
result
decreas
cardiac
output
defici
preload
order
maintain
oxygen
deliveri
tissu
compens
reduct
oxygen
carri
capac
increas
region
blood
flow
tissu
also
abl
increas
oxygen
extract
respons
decreas
oxygen
deliveri
cardiac
circul
extrem
high
oxygen
extract
ratio
rest
vasodilatori
capac
respons
increas
demand
limit
normal
physiolog
condit
heart
reli
sympathet
discharg
increas
myocardi
contractil
heart
rate
system
vascular
tone
compens
decreas
oxygen
deliveri
left
ventricular
dysfunct
andor
coronari
arteri
diseas
abil
heart
increas
cardiac
output
coronari
arteri
blood
flow
respons
sever
anemia
compromis
thu
anemia
poorli
toler
set
cardiovascular
diseas
red
blood
cell
transfus
would
expect
increas
oxygen
deliveri
therebi
prevent
tissu
hypoxia
organ
failur
associ
anemia
howev
oxygen
deliveri
transfus
rbc
equival
nativ
red
blood
cell
oxygen
consumpt
reliabl
increas
follow
rbc
transfus
critic
ill
adult
rbc
transfus
result
increas
oxygen
consumpt
calcul
fick
equat
increas
oxygen
util
measur
indirect
calorimetri
transfus
store
rbc
may
consist
increas
tissu
oxygen
avail
recent
studi
attempt
determin
optim
hemoglobin
concentr
critic
ill
adult
canadian
critic
care
trial
group
tricc
trial
report
maintain
hemoglobin
concentr
gdl
critic
ill
adult
patient
result
compar
mortal
rate
patient
year
age
less
sever
ill
half
like
die
treat
restrict
regimen
crit
studi
found
rbc
transfus
independ
associ
longer
icu
stay
hospit
increas
mortal
even
control
sever
ill
compar
result
found
anoth
adult
studi
wors
outcom
associ
higher
number
transfus
rbc
unit
dose
depend
manner
describ
patient
ischem
cardiovascular
diseas
thought
unabl
compens
anemia
histor
hemoglobin
level
typic
maintain
gdl
patient
howev
conflict
evid
whether
patient
actual
benefit
higher
hemoglobin
level
subgroup
analysi
patient
sever
ischem
heart
diseas
tricc
trial
found
statist
signific
differ
mortal
restrict
versu
liber
transfus
group
contrast
recent
retrospect
studi
elderli
patient
admit
acut
myocardi
infarct
found
lower
mortal
rate
patient
transfus
low
hemoglobin
gdl
compar
appear
maintain
hemoglobin
concentr
greater
gdl
critic
ill
adult
patient
without
concurr
cardiovascular
diseas
benefit
increas
morbid
mortal
associ
transfus
patient
howev
patient
acut
coronari
insuffici
may
benefit
increas
transfus
support
appear
maintain
hemoglobin
greater
gdl
critic
ill
adult
patient
without
concurr
cardiovascular
diseas
benefit
increas
morbid
mortal
associ
transfus
patient
howev
patient
acut
coronari
insuffici
may
benefit
increas
transfus
support
children
data
regard
hemoglobin
level
clinic
diagnosi
benefit
rbc
transfus
outweigh
risk
critic
ill
pediatr
patient
begin
accumul
survey
pediatr
intensivist
reveal
transfus
recommend
hemoglobin
concentr
rang
gdl
hemodynam
instabl
end
organ
insuffici
prompt
need
transfus
observ
studi
critic
ill
children
examin
hemoglobin
level
gdl
found
control
sever
ill
transfus
associ
increas
day
oxygen
use
mechan
ventil
vasoact
agent
infus
length
stay
tripicu
studi
stabl
critic
ill
children
random
hemoglobin
concentr
threshold
gdl
red
blood
cell
transfus
demonstr
decreas
transfus
requir
lower
threshold
group
without
increas
advers
outcom
current
mostli
empir
approach
reserv
red
blood
cell
transfus
children
one
follow
acut
hemorrhag
chronic
blood
loss
result
hemodynam
instabl
clinic
evid
hypovolemia
pair
low
hemoglobin
cyanot
cardiac
condit
arteri
blood
fulli
oxygent
compound
acut
cardiopulmonari
insult
low
hemoglobin
hypox
respiratori
failur
pair
low
hemoglobin
rbc
transfus
reserv
children
acut
hemorrhag
chronic
blood
loss
result
hemodynam
instabl
clinic
evid
hypovolemia
pair
low
hemoglobin
cardiac
mix
lesion
deoxygen
blood
perfus
tissu
compound
acut
cardiopulmonari
insult
hypox
respiratori
failur
pair
low
hemoglobin
whole
blood
contain
rbc
plasma
white
blood
cell
wbc
platelet
given
increas
red
blood
cell
mass
plasma
volum
whole
blood
rare
indic
except
acut
massiv
hemorrhag
pack
rbc
prbc
produc
remov
plasma
whole
blood
pack
rbc
unit
commonli
util
treatment
anemia
deliv
increas
rbc
mass
smaller
volum
pack
rbc
compon
contain
contamin
wbc
platelet
cellular
compon
bioactiv
substanc
contamin
white
blood
cell
may
incit
hemolysi
result
leakag
potassium
toxic
oxygen
radic
destruct
enzym
storag
media
white
blood
cell
also
implic
immunosuppress
postop
infect
high
level
cytokin
tnf
found
storag
media
thought
respons
febril
transfus
reaction
leukoreduct
irradi
cover
alloimmun
occur
dispar
red
cell
antigen
blood
donor
blood
recipi
exist
antibodi
antigen
develop
blood
recipi
patient
blood
recipi
becom
alloimmun
immunemedi
hemolysi
occur
follow
later
exposur
sensit
donor
antigen
alloimmun
estim
complic
rbc
transfus
gener
popul
limit
subsequ
red
blood
cell
transfus
therapi
alloimmun
occur
frequent
patient
receiv
multipl
rbc
transfus
throughout
life
crossmatch
blood
patient
transfus
time
difficult
alloimmun
patient
limit
amount
speed
blood
product
avail
transfus
need
support
wound
militari
gave
rise
creation
modern
transfus
medicin
media
use
store
rbc
citrat
anticoagul
dextros
today
cellular
nutrient
ad
increas
lifespan
store
product
day
nonetheless
rbc
store
ex
vivo
still
undergo
biochem
morpholog
chang
rbc
storag
lesion
hinder
rbc
transport
oxygen
deliveri
storag
erythrocyt
depriv
energi
seri
morpholog
chang
occur
includ
loss
normal
biconcav
disc
shape
crenat
spicul
format
produc
echinocyt
swell
echinocyt
form
spheroechinocyt
eventu
cell
shed
spicul
lipid
vesicl
spherocyt
form
spherocyt
low
surfac
volum
ratio
unabl
deform
transvers
microcircul
increas
osmot
fragil
result
hemolysi
addit
endogen
antioxid
lost
result
damag
cytoskelet
protein
membran
phospholipid
hemoglobin
also
convert
methemoglobin
bind
oxygen
final
store
erythrocyt
deplet
increas
oxygen
affin
thu
hinder
offload
oxygen
tissu
twenti
percent
rbc
unit
held
american
blood
bank
transfus
center
day
old
older
unit
rel
rare
blood
type
ie
consist
older
multipl
studi
found
associ
increas
mortal
increas
length
stay
multipl
organ
system
failur
increas
infect
impair
tissu
oxygen
util
length
rbc
storag
analyt
cohort
analysi
tripicu
studi
critic
ill
pediatr
patient
storag
durat
greater
day
independ
associ
increas
multipl
organ
dysfunct
syndrom
mod
storag
day
associ
higher
mortal
prospect
random
trial
critic
ill
adult
children
examin
effect
storag
durat
clinic
outcom
current
undertaken
result
guid
futur
recommend
regard
age
blood
cell
transfus
adult
averag
blood
volum
mlkg
one
unit
pack
rbc
gener
rais
hemoglobin
gdl
pediatr
blood
volum
approxim
mlkg
mlkg
prbc
transfus
gener
increas
hemoglobin
child
gdl
adult
patient
typic
receiv
unit
prbc
transfus
pediatr
patient
usual
transfus
mlkg
prbc
protocol
give
prbc
transfus
h
stabl
adult
pediatr
patient
hypotens
patient
practic
gener
infus
half
volum
rapidli
bolu
remaind
hour
patient
respond
clinic
pediatr
blood
volum
approxim
mlkg
mlkg
prbc
gener
increas
child
hemoglobin
gdl
although
gener
guidelin
discuss
appropri
treatment
critic
ill
child
demand
care
individu
approach
import
note
volum
well
hematocrit
unit
prbc
may
vari
significantli
within
institut
also
import
take
account
averag
hematocrit
particular
unit
awar
actual
volum
given
transfus
unit
institut
volum
one
unit
filter
prbc
typic
ml
hematocrit
unit
wash
filter
red
cell
ml
hematocrit
approxim
blood
bank
concentr
prbc
neonat
process
rais
hematocrit
volum
transfus
blood
bank
automat
util
volumedeplet
prbc
unit
hematocrit
transfus
children
less
year
age
upon
special
request
specif
criteria
met
volumedeplet
unit
util
year
number
formula
avail
predict
volum
transfus
red
cell
need
achiev
particular
hemoglobin
hematocrit
tradit
formula
rbc
replac
tradit
formula
rbc
replac
volum
prbc
ml
ebv
ml
desir
hct
actual
hct
hct
prbc
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
text
volum
text
text
prbc
ml
text
ebv
ml
time
frac
text
desir
text
hct
text
actual
text
hct
text
text
hct
text
text
prbc
end
document
ebv
estim
blood
volum
hct
hematocrit
hct
prbc
usual
recent
studi
found
formula
underestim
requir
volum
author
propos
follow
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
begin
array
l
text
volum
pack
cell
transfus
left
text
ml
right
text
weight
left
text
kg
right
time
text
desir
rise
hemoglobin
left
text
gdl
right
end
array
end
document
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
begin
array
l
text
volum
pack
cell
transfus
left
text
ml
right
text
weight
left
text
kg
right
time
text
desir
rise
hct
left
right
end
array
end
document
note
formula
appli
red
cell
unit
median
hematocrit
hemoglobin
gdl
depend
upon
averag
hematocrit
prbc
unit
given
institut
appropri
formula
use
calcul
volum
prbc
transfus
practition
alway
keep
mind
rbc
transfus
without
risk
infect
transfus
reaction
acut
lung
injuri
alloimmun
among
associ
complic
discuss
later
chapter
primari
hemostasi
depend
upon
platelet
platelet
transfus
indic
patient
compromis
decreas
platelet
product
increas
platelet
destruct
andor
platelet
dysfunct
gener
indic
platelet
transfus
includ
acut
hemorrhag
associ
thrombocytopenia
prophylaxi
nonbleed
patient
sever
thrombocytopenia
prophylaxi
thrombocytopen
patient
requir
surgic
intervent
platelet
transfus
also
use
children
normal
platelet
count
experi
bleed
associ
qualit
platelet
defect
excess
bleed
undergo
cardiopulmonari
bypass
extracorpor
membran
oxygen
ecmo
children
undergo
ecmo
typic
maintain
platelet
count
greater
even
bleed
contrast
children
undergo
cardiopulmonari
bypass
gener
given
platelet
transfus
unless
activ
bleed
platelet
count
less
gener
indic
platelet
transfus
includ
acut
hemorrhag
associ
thrombocytopenia
prophylaxi
nonbleed
patient
sever
thrombocytopenia
prophylaxi
thrombocytopen
patient
requir
surgic
intervent
platelet
transfus
gener
indic
children
idiopath
thrombocytopen
purpura
itp
unless
lifethreaten
hemorrhag
sinc
transfus
platelet
like
endogen
platelet
also
destroy
immun
mechan
treatment
modal
use
platelet
transfus
contraind
thrombot
thrombocytopen
purpura
ttp
infus
platelet
may
contribut
ongo
thrombosi
risk
spontan
hemorrhag
highest
platelet
count
platelet
gener
transfus
level
thrombocytopenia
whether
patient
bleed
platelet
count
often
associ
hemorrhag
secondari
trauma
invas
procedur
ulcer
bleed
tendenc
variabl
platelet
count
absenc
bleed
anticip
surgic
procedur
typic
accept
threshold
platelet
transfus
studi
thrombocytopenia
patient
acut
leukemia
use
threshold
prophylact
transfus
instead
approach
result
fewer
transfus
overal
differ
rate
sever
bleed
remiss
mortal
therefor
use
platelet
guidelin
prophylact
transfus
children
appear
appropri
lifethreaten
bleed
patient
platelet
count
maintain
difficulti
platelet
clump
bacteri
contamin
storag
condit
made
platelet
transfus
unavail
late
except
given
fresh
whole
blood
develop
gasperm
plastic
allow
platelet
safe
separ
whole
blood
store
room
temperatur
day
constant
agit
prevent
clump
shorter
shelf
life
platelet
due
storag
room
temperatur
increas
risk
bacteri
growth
platelet
refriger
sever
compromis
posttransfus
platelet
surviv
due
platelet
activ
clump
platelet
unit
avail
platelet
concentr
typic
obtain
whole
blood
donat
singl
donor
platelet
collect
platelet
apheresi
produc
platelet
concentr
red
cell
separ
whole
blood
use
softspin
techniqu
platelet
undergo
hardspin
separ
plasma
form
platelet
concentr
suspend
approxim
ml
plasma
unit
contain
approxim
platelet
platelet
apheresi
multipl
unit
platelet
collect
singl
donor
therebi
reduc
alloimmun
result
multipl
donor
exposur
singl
donor
platelet
expens
platelet
concentr
typic
reserv
patient
requir
hlamatch
unit
like
rbc
transfus
platelet
transfus
also
carri
risk
infect
alloimmun
decemb
colleg
american
pathologist
mandat
platelet
product
inspect
bacteri
contamin
accept
standard
test
cultur
platelet
compon
wait
h
result
releas
platelet
transfus
platelet
compon
also
contain
white
blood
cell
may
caus
allerg
reaction
advent
univers
leukoreduct
incid
effect
follow
platelet
transfus
greatli
decreas
see
approxim
onehalf
patient
receiv
platelet
concentr
develop
alloimmun
alloimmun
occur
antibodi
recipi
serum
react
hla
class
antigen
donor
platelet
membran
decreas
platelet
surviv
function
patient
histori
immunogen
stimuli
blood
product
pregnanc
genet
characterist
appear
determin
whether
alloimmun
occur
leukoreduct
platelet
product
also
significantli
reduc
occurr
alloimmun
approxim
see
patient
alloimmun
current
standard
care
util
either
hlamatch
crossmatch
singl
donor
platelet
sdp
futur
platelet
transfus
typic
one
unit
platelet
transfus
per
kg
bodi
weight
infant
children
rais
platelet
count
approxim
six
unit
platelet
standard
adult
patient
rais
platelet
count
h
infus
unit
platelet
typic
rais
platelet
count
approxim
adult
platelet
transfus
consid
success
stop
bleed
posttransfus
correct
count
increment
greater
platelet
achiev
typic
one
unit
platelet
transfus
per
kg
bodi
weight
infant
children
rais
platelet
count
approxim
refractori
platelet
transfus
demonstr
lack
signific
increas
platelet
count
follow
transfus
major
concern
patient
hematolog
diseas
requir
continu
platelet
support
immun
alloimmun
nonimmun
process
contribut
platelet
refractori
nonimmun
caus
platelet
refractori
includ
infect
fever
consumpt
dissemin
intravascular
coagul
splenomegali
cytotox
drug
antifung
amphotericin
antibiot
approxim
onethird
transfus
platelet
sequest
spleen
may
compound
poor
respons
platelet
transfus
clot
factor
defici
occur
commonli
pediatr
critic
care
patient
coagul
protein
often
diminish
set
trauma
secondari
dilut
follow
massiv
blood
transfus
trauma
tissu
thromboplastin
plasminogen
activ
releas
tissu
devit
trigger
coagul
cascad
consumpt
coagul
factor
trauma
burn
patient
extens
tissu
injuri
often
develop
dissemin
intravascular
coagul
dic
coagul
protein
consum
hypothermia
often
develop
patient
inhibit
serin
proteas
activ
lead
decreas
activ
coagul
factor
prolong
pt
ptt
sever
sepsi
may
also
activ
coagul
cascad
caus
consumpt
coagulopathi
andor
dic
replac
coagul
protein
accomplish
infus
fresh
frozen
plasma
ffp
fresh
frozen
plasma
deriv
whole
blood
donat
place
within
h
collect
viabl
month
fresh
frozen
plasma
contain
coagul
factor
ml
unit
factor
activ
natur
occur
inhibitor
volum
one
bag
ffp
ml
larger
volum
ml
collect
via
singl
donor
plasmapheresi
older
children
singl
donor
unit
prefer
use
two
bag
ffp
sinc
approach
limit
donor
exposur
indic
use
ffp
children
includ
support
episod
dic
factor
replac
concentr
avail
therapeut
plasma
exchang
circumst
ttp
warfarin
revers
stop
activ
bleed
surgeri
ffp
use
volum
expand
prothrombin
time
pt
time
midpoint
normal
rang
activ
partial
thromboplastin
time
aptt
time
upper
limit
normal
rang
ffp
consid
bleed
present
prior
invas
procedur
import
recogn
refer
rang
coagul
factor
vari
age
adult
standard
appli
pediatr
patient
pediatr
patient
typic
dose
ffp
mlkg
note
everi
unit
platelet
contain
plasma
protein
volum
equival
one
bag
ffp
platelet
also
administ
smaller
volum
ffp
need
indic
use
ffp
children
includ
support
episod
dic
factor
replac
concentr
avail
therapeut
plasma
exchang
circumst
ttp
warfarin
revers
stop
activ
bleed
surgeri
ffp
use
volum
expand
cryoprecipit
cold
precipit
protein
fraction
obtain
ffp
thaw
resuspend
ml
residu
plasma
supernat
refrozen
store
year
cryoprecipit
contain
factor
viii
von
willebrand
factor
vwf
fibrinogen
factor
xiii
fibronectin
use
replac
therapi
protein
low
set
activ
bleed
prepar
invas
surgic
procedur
hypofibrinogenemia
may
secondari
dilut
massiv
transfus
may
occur
set
dic
fibrinogen
level
mgdl
adequ
hemostasi
cryoprecipit
given
hypofibrinogenemia
associ
bleed
bleed
risk
dysfibrinogenemia
also
context
bleed
surgeri
anoth
indic
cryoprecipit
cryoprecipit
similarli
use
factor
xiii
defici
factor
xiii
unavail
cryoprecipit
also
use
patient
von
willebrand
diseas
refractori
deaminodarginin
vasopressin
ddavp
ddavp
indic
andor
viral
inactiv
plasmaderiv
factor
viii
concentr
avail
cryoprecipit
longer
use
children
factor
viii
defici
factor
viii
concentr
wide
avail
cryoprecipit
contain
factor
viii
von
willebrand
factor
vwf
fibrinogen
factor
xiii
fibronectin
use
replac
therapi
protein
low
set
activ
bleed
prepar
invas
surgic
procedur
amount
cryoprecipit
necessari
correct
deficit
fibrinogen
calcul
accord
formula
desir
increment
gl
number
bag
plasma
volum
l
good
rule
thumb
transfus
one
bag
cryoprecipit
everi
kg
bodi
weight
halflif
fibrinogen
day
recoveri
transfus
product
specif
content
vwf
singl
bag
cryoprecipit
unknown
standard
dose
cryoprecipit
treat
von
willebrand
diseas
one
bag
per
kg
bodi
weight
year
great
interest
polymorphonuclear
leukocyt
pmn
transfus
treatment
prevent
lifethreaten
infect
neutropen
patient
initi
inabl
obtain
adequ
number
pmn
limit
leukapheresi
techniqu
hinder
use
pmn
transfus
howev
treat
donor
granulocyt
colonystimul
factor
gcsf
corticosteroid
prior
leukapheresi
shown
elev
donor
pmn
count
increas
pmn
collect
yield
costeffect
regimen
increas
pmn
mobil
donor
appear
singl
dose
gcsf
subcutan
plu
dexamethason
mg
po
h
prior
leukapheresi
transfus
center
reli
continuousflow
centrifug
leukapheresi
granulocyt
collect
current
goal
transfus
pmn
immedi
leukapheresi
yet
evid
suggest
granulocyt
safe
store
h
time
control
trial
guid
optim
storag
durat
transfus
pmn
found
restor
peripher
blood
pmn
count
normal
rang
neutropen
recipi
transfus
granulocyt
also
demonstr
normal
function
evidenc
abil
migrat
tissu
site
vivo
measur
buccal
pmn
respons
effect
granulocyt
transfus
therapi
treat
infect
sever
neutropen
patient
remain
question
literatur
compos
uncontrol
studi
small
sampl
size
variabl
dose
qualiti
pmn
variabl
underli
diseas
treatment
type
infect
take
limit
account
one
metaanalysi
conclud
subject
bacteri
sepsi
benefit
granulocyt
therapi
patient
fungal
infect
respond
prospect
phase
iii
studi
patient
sever
neutropenia
receiv
granulocyt
transfus
uncontrol
sepsi
found
infect
clear
patient
fourteen
seventeen
patient
bacteremia
recov
patient
fungemia
clear
infect
recent
evid
suggest
granulocyt
transfus
therapi
may
effect
neutropen
patient
lifethreaten
bacteri
fungal
infect
larg
control
trial
necessari
recommend
made
transfus
reaction
secondari
granulocyt
transfus
similar
associ
blood
product
sever
reaction
hypotens
pulmonari
infiltr
respiratori
distress
occur
transfus
especi
granulocyt
given
concomitantli
amphotericin
b
rbc
platelet
transfus
alloimmun
also
concern
test
antibodi
abo
antigen
leukoagglutin
well
irradi
pmn
product
prior
transfus
decreas
incid
problem
albumin
deriv
pool
human
plasma
indic
volum
expans
colloid
replac
albumin
solut
gener
given
emerg
treatment
shock
hypovolemia
acut
manag
burn
indic
includ
acut
hypotens
acut
chronic
liver
failur
follow
paracentesi
ascit
mainten
blood
volum
plasma
exchang
procedur
therapeut
phlebotomi
polycythemia
combin
diuret
induc
diuresi
fluid
overload
proteinlos
enteropathi
nephropathi
acuteonchron
liver
failur
elev
protein
level
select
patient
acut
respiratori
distress
syndrom
ard
cardiovascular
collaps
secondari
hypovolemia
extracorpor
circul
albumin
gener
given
emerg
treatment
shock
hypovolemia
acut
manag
burn
indic
includ
acut
hypotens
acut
chronic
liver
failur
follow
paracentesi
ascit
mainten
blood
volum
plasma
exchang
procedur
therapeut
phlebotomi
polycythemia
combin
diuret
induc
diuresi
fluidoverload
proteinlos
enteropathi
nephropathi
acuteonchron
liver
failur
elev
protein
level
select
patient
ard
cardiovascular
collaps
secondari
hypovolemia
extracorpor
circul
use
albumin
fluid
resuscit
critic
ill
patient
nonhemorrhag
hypovolemia
subject
debat
cochran
databas
system
review
examin
effect
colloid
versu
crystalloid
solut
patient
surviv
specif
examin
studi
critic
ill
patient
hypovolemia
burn
hypoalbuminemia
increas
risk
death
albumintr
group
patient
categori
suggest
albumin
may
increas
mortal
critic
ill
patient
salin
versu
albumin
fluid
evalu
safe
trial
random
patient
receiv
either
albumin
normal
salin
fluid
resuscit
death
primari
outcom
signific
differ
new
singl
organ
multiorgan
system
failur
number
day
icu
number
total
hospit
day
day
mechan
ventil
day
requir
renal
replac
therapi
found
insuffici
power
detect
differ
predefin
group
traumat
brain
injuri
trauma
patient
result
safe
trial
indic
albumin
salin
clinic
equival
intravascular
volum
replac
critic
ill
patient
light
fact
cost
albumin
approxim
time
greater
crystalloid
fluid
short
suppli
use
albumin
crystalloid
fluid
increas
intravascular
volum
nonbleed
patient
without
hypoproteinemia
burn
support
literatur
intraven
immun
globulin
ivig
commonli
administ
replac
therapi
immun
globulin
defici
patient
suppress
autoimmun
inflammatori
process
immunolog
compet
individu
treatment
immun
defici
ivig
replac
miss
antibodi
immunomodul
ivig
bind
mononuclear
phagocyt
fc
receptor
competit
inhibit
fc
receptor
bind
cell
associ
antibodi
prevent
phagocytosi
ivig
compos
subclass
igg
major
compon
involv
viru
inactiv
complement
activ
tissu
protect
postul
action
ivig
includ
increas
complement
absorpt
regul
immunoglobulin
product
neutral
virus
enhanc
suppressor
cell
inhibit
lymphocyt
prolifer
decreas
product
activ
ivig
commonli
administ
replac
therapi
immun
globulin
defici
patient
suppress
autoimmun
inflammatori
process
immunolog
compet
individu
ivig
deriv
pool
human
plasma
hundr
thousand
donor
isol
cohnoncley
process
cold
ethanol
fraction
manufactur
ivig
entail
sequenti
precipit
fraction
isol
igg
plasma
protein
although
trace
iga
igm
igd
ige
persist
ivig
product
ethanol
remov
freezedri
produc
stabl
intermedi
insolubl
igg
aggreg
requir
process
ivig
prepar
differ
properti
depend
upon
approach
process
ie
solvent
deterg
pasteur
nanofiltr
ultrafiltr
etc
consid
equival
efficaci
product
undergo
viru
inactiv
remov
potenti
viral
transmiss
still
exist
seven
polyclon
ivig
prepar
fda
approv
avail
us
addit
four
hyperimmun
product
indic
treatment
cytomegaloviru
hepat
b
hbig
respiratori
syncyti
viru
rsvivig
rh
prophylaxi
rhogham
common
use
ivig
children
primari
secondari
humor
immunodefici
state
hematolog
diseas
itp
steroidresist
autoimmun
hemolyt
anemia
opportunist
infect
prophylaxi
bone
marrow
transplant
recipi
neonat
alloimmun
thrombocytopenia
neonat
sepsi
provid
immatur
infant
antibodi
kawasaki
diseas
guillainbarr
syndrom
diseas
less
clear
indic
includ
intract
seizur
myasthenia
gravi
inflammatori
myopathi
system
lupu
erythematosi
antiphospholipid
antibodi
syndrom
rheumatoid
arthriti
inflammatori
bowel
diseas
system
vascul
chronic
idiopath
urticaria
asthma
bullou
pemphigoid
use
ivig
immunomodul
septic
state
gener
great
interest
specul
ivig
may
inactiv
toxin
stimul
leukocyt
serum
bactericid
activ
interfer
cytokin
effect
prevent
excess
complement
activ
though
proven
efficaci
headach
myalgia
nausea
vomit
facial
flush
occur
ivig
infus
may
allevi
slow
stop
infus
acetaminophen
diphenhydramin
andor
hydrocortison
prior
infus
may
lessen
reaction
asept
mening
transient
hemiplegia
acut
chronic
renal
failur
preexist
renal
diseas
anaphylaxi
select
iga
defici
report
treat
immunodefici
mgkg
iv
week
typic
mainten
dose
goal
trough
serum
igg
level
mgdl
itp
treat
higher
dose
ivig
gener
gkg
iv
complic
note
frequent
therapi
dose
rate
infus
depend
upon
prepar
patient
toler
infus
rate
rang
mlkgmin
prepar
higher
osmol
sucros
concentr
infus
slowli
iga
defici
patient
may
antiiga
antibodi
sever
reaction
ivig
therefor
person
receiv
ivig
serum
level
iga
measur
iga
defici
receiv
ivig
product
lowest
iga
content
possibl
protein
c
vitamin
kdepend
glycoprotein
synthes
hepatocyt
protein
c
circul
inact
form
activ
thrombinthrombomodulin
complex
vascular
endotheli
cell
activ
protein
c
three
main
effect
antithrombosi
inactiv
factor
va
viiia
antiinflammatori
effect
secondari
varieti
mechan
blockag
cytokin
format
selectin
activ
transloc
enhanc
fibrinolysi
inactiv
plasminogen
activ
inhibit
thrombinactiv
fibrinolysi
inhibitor
tafi
sever
sepsi
known
caus
acquir
protein
c
defici
lower
level
associ
increas
morbid
mortal
septic
patient
sever
sepsi
may
also
impair
convers
protein
c
activ
form
knowledg
role
activ
protein
c
play
sepsi
prompt
trial
recombin
human
activ
protein
c
rhapc
also
known
activ
drotrecogin
alfa
infus
septic
patient
adult
studi
recombin
human
activ
protein
c
worldwid
evalu
sever
sepsi
prowess
trial
demonstr
decreas
day
caus
mortal
patient
receiv
rhapc
open
label
studi
pediatr
patient
purpurafulminansassoci
meningococcemia
demonstr
decreas
morbid
mortal
rhapc
treat
patient
view
promis
studi
random
doubl
blind
placebo
control
trial
rhapc
pediatr
patient
sepsi
perform
investig
stop
interim
analysi
reveal
treatment
futil
increas
cn
hemorrhag
treat
subject
prowessshock
trial
follow
origin
studi
also
find
mortal
benefit
treat
subject
sinc
benefit
establish
later
trial
demonstr
increas
risk
seriou
bleed
death
activ
drotrecogin
alfa
xigri
taken
worldwid
market
octob
clinic
trial
involv
drug
discontinu
center
red
blood
cell
compon
filter
shortli
collect
elimin
leukocyt
process
call
prestorag
leukoreduct
leukoreduc
red
blood
compon
contain
leukocytesunit
platelet
compon
filter
undergo
specif
apheresi
collect
protocol
reduc
number
leukocyt
leukoreduc
platelet
compon
contain
leukocytesunit
gener
accept
indic
leukoreduct
blood
product
includ
reduct
hla
alloimmun
risk
patient
requir
long
term
platelet
support
potenti
organ
transplant
recipi
reduct
cmv
transmiss
atrisk
patient
reduct
rate
recurr
febril
nonhemolyt
transfus
reaction
controversi
indic
includ
prevent
prion
viral
reactiv
prevent
postop
infect
reduct
tumor
recurr
prevent
bacteri
infect
reduct
transfusionrel
lung
injuri
reduct
transfusionassoci
graft
versu
host
diseas
gener
accept
indic
leukoreduct
blood
product
includ
reduct
hla
alloimmun
risk
patient
requir
long
term
platelet
support
potenti
organ
transplant
recipi
reduct
cmv
transmiss
atrisk
patient
reduct
rate
recurr
febril
nonhemolyt
transfus
reaction
reduct
inhospit
mortal
seriou
nosocomi
infect
follow
adopt
leukoreduct
blood
product
canada
howev
cost
effect
univers
leukoreduct
remain
controversi
addit
financi
burden
consider
loss
blood
element
filtrat
leukocytedeplet
rbc
unit
deliv
statist
smaller
total
rbc
mass
nonleukoreduc
unit
despit
debat
januari
us
depart
health
human
servic
dhh
advisori
committe
blood
safeti
avail
acbsa
recommend
univers
leukoreduct
cellular
blood
product
unit
state
note
previous
blood
filtrat
decreas
elimin
wbc
contamin
viabl
tlymphocyt
blood
product
transfus
immunosuppress
patient
prolifer
caus
transfusionassoci
graftversushost
diseas
tagvhd
tagvhd
character
skin
gastrointestin
hepat
andor
hematolog
damag
occur
day
follow
transfus
associ
high
mortal
gy
radiat
appli
cellular
blood
compon
prevent
donor
tlymphocyt
divid
therebi
prevent
gvhd
recipi
ffp
cryoprecipit
requir
irradi
neither
contain
viabl
wbc
caus
tagvhd
irradi
decreas
rbc
viabil
caus
potassium
leakag
thu
limit
storag
durat
day
reason
blood
product
irradi
prior
transfus
indic
irradi
blood
product
includ
mismatch
hla
haplotyp
donor
recipi
patient
immunocompromis
chemotherapeut
regimen
hematopoiet
transplant
patient
neonat
patient
congenit
cellmedi
immunodefici
institut
patient
receiv
solid
organ
transplant
also
receiv
irradi
blood
product
institut
blood
product
irradi
clinician
must
rememb
irradi
elimin
virus
indic
irradi
blood
product
includ
mismatch
hla
haplotyp
donor
recipi
patient
immunocompromis
chemotherapeut
regimen
hematopoiet
transplant
patient
neonat
patient
congenit
cellmedi
immunodefici
rbc
product
also
contain
small
amount
residu
plasma
protein
protein
may
produc
allerg
reaction
transfus
recipi
wash
elimin
protein
rbc
product
indic
patient
histori
sever
recurr
allerg
reaction
associ
rbc
transfus
iga
defici
iga
defici
blood
unavail
host
antiiga
antibodi
react
iga
donor
transfus
product
redcel
activ
pediatr
commonli
appreci
necrot
enterocol
invas
pneumococc
infect
caus
antigen
expos
rbc
surfac
antit
antibodi
donor
plasma
may
caus
hemolysi
complementdepend
autoimmun
hemolyt
anemia
wash
prevent
infus
complement
transfus
contain
larg
quantiti
cellular
solubl
antigen
alloantigen
bioactiv
substanc
proinflammatori
andor
immunosuppress
properti
consequ
allogen
blood
transfus
induc
clinic
signific
alter
recipi
immun
function
term
transfusionrelatedimmun
modul
trim
decreas
helpertosuppressor
tlymphocyt
ratio
decreas
natur
killer
cell
function
defect
antigen
present
reduc
cellmedi
immun
occur
secondari
trim
immunomodul
secondari
rbc
transfus
first
suspect
increas
renal
allograft
surviv
note
rbc
transfus
suspicion
confirm
perform
prospect
random
control
studi
illustr
increas
allograft
surviv
follow
rbc
transfus
increas
allograft
surviv
follow
rbc
transfus
rais
question
whether
trim
might
also
increas
cancer
recurr
via
downregul
host
immun
surveil
target
malign
cell
random
control
trial
support
increas
cancer
recurr
postop
infect
secondari
periop
allogen
blood
transfus
howev
difficulti
observ
bia
patient
select
make
difficult
exclud
confound
variabl
studi
investig
necessari
determin
whether
leukoreduct
limit
immunemodul
rbc
transfus
hemolyt
reaction
result
abo
incompat
acquir
alloantibodi
antirh
antijka
also
caus
hemolyt
reaction
hemolyt
reaction
donor
red
blood
cell
antigen
form
complex
recipi
antibodi
lead
cell
death
abo
mismatch
carri
signific
risk
morbid
mortal
blood
transfus
caus
hemolysi
death
hemolysi
cellular
product
releas
damag
renal
tubular
cell
may
lead
hemoglobinuria
acut
tubular
necrosi
renal
failur
immunolog
respons
gener
antigenantibodi
complex
may
trigger
system
consumpt
coagulopathi
dic
sever
hemolyt
transfus
reaction
manifest
fever
chill
rigor
hypotens
tachycardia
respiratori
distress
hemoglobinuria
andor
bleed
hemolyt
transfus
reaction
suspect
transfus
must
stop
immedi
treatment
involv
volum
support
isoton
fluid
prevent
hypotens
ensur
urin
output
mlh
adult
patient
mlkgh
pediatr
patient
inotrop
support
consid
set
poor
urinari
output
despit
adequ
volum
resuscit
support
care
often
necessari
prevent
cardiopulmonari
complic
dic
treat
appropri
febril
nonhemolyt
transfus
reaction
fnhtr
occur
approxim
rbc
transfus
febril
nonhemolyt
transfus
reaction
defin
increas
temperatur
least
transfus
absenc
anoth
caus
reaction
gener
mild
resolv
spontan
caus
signific
discomfort
febril
nonhemolyt
transfus
reaction
may
character
fever
chill
dyspnea
occur
within
h
transfus
reaction
cytokin
mediat
usual
prevent
use
leukocytereduc
blood
product
sinc
hemolyt
reaction
also
manifest
fever
manag
includ
stop
transfus
evalu
possibl
transfus
reaction
febril
nonhemolyt
transfus
reaction
often
success
treat
antipyret
antihistamin
andor
meperidin
rigor
incid
anaphylact
transfus
reaction
per
transfus
platelet
compon
ffp
respons
highest
rate
reaction
allergicanaphylact
transfus
reaction
presum
secondari
plasma
protein
clinic
reaction
similar
anaphylaxi
caus
manifest
rapid
progress
hypotens
shock
angioedema
respiratori
distress
manag
includ
stop
transfus
administr
subcutan
intramuscular
epinephrin
airway
manag
oxygen
volum
inotropicvasopressor
support
transfus
reaction
includ
volum
overload
hypothermia
citrat
toxic
hyperkalemia
transfus
relat
acut
lung
injuri
care
assess
continu
monitor
vascular
volum
statu
pulmonari
renal
function
electrolyt
balanc
necessari
infus
blood
product
intensivist
must
prepar
provid
oxygen
ventil
support
diuret
necessari
neonat
infant
greatest
risk
volum
overload
hypothermia
transfus
refriger
blood
standard
practic
transfus
mlkg
rbc
rate
mlkgh
slower
rate
transfus
consid
children
anemia
sever
develop
indol
natur
classic
exampl
occur
infant
fed
iron
poor
cow
milk
cow
milk
caus
occult
intestin
blood
loss
lead
slowli
progress
profound
anemia
present
hemoglobin
valu
often
less
gdl
rapid
transfus
may
appropri
acut
volum
resuscit
risk
hypothermia
increas
larg
volum
transfus
especi
central
cathet
hypothermia
avoid
use
blood
warmer
citrat
bind
calcium
anticoagul
rbc
plasma
storag
media
larg
volum
transfus
citrat
lead
hypocalcemia
citrat
metabol
liver
bicarbon
consequ
liver
failur
may
increas
risk
citrat
toxic
addit
simultan
infus
calcium
tube
contain
blood
product
directli
unit
may
caus
microemboli
form
coadministr
lactat
ringer
solut
blood
also
contraind
due
high
calcium
content
red
cell
lyse
prolong
storag
caus
increas
extracellular
potassium
present
unit
estim
potassium
level
may
rise
rbc
unit
much
meqlday
first
week
storag
potassium
load
particularli
danger
neonat
patient
renal
insuffici
pulmonari
complic
blood
transfus
compris
spectrum
diseas
rang
sever
mild
pulmonari
edema
transfus
relat
acut
lung
injuri
trali
transfus
relat
acut
lung
injuri
defin
acut
respiratori
compromis
onset
dyspnea
hypoxia
noncardiogen
pulmonari
edema
within
h
transfus
plasmacontain
blood
product
whole
blood
rbc
platelet
ffp
cryoprecipit
ivig
potenti
caus
trali
incid
cite
transfus
postul
trali
result
immunogen
respons
lead
pulmonari
capillari
endotheli
damag
capillari
leak
edema
format
thought
donor
antibodi
react
antigen
recipi
wbc
result
complement
activ
granulocyt
chemotaxin
attract
leukocyt
pulmonari
circul
neutrophil
lysosom
enzym
damag
capillari
endothelium
result
capillari
leak
fluid
pulmonari
alveoli
diagnosi
trali
base
clinic
criteria
made
primarili
exclud
possibl
condit
propos
clinic
criteria
diagnosi
trali
includ
acut
onset
pulmonari
insuffici
within
h
hypoxemia
specif
mm
hg
bilater
fluffi
infiltr
chest
radiographi
pulmonari
arteri
wedg
pressur
mm
hg
absenc
left
atrial
hypertens
laboratori
analysi
donor
recipi
blood
sampl
may
support
diagnosi
acut
respiratori
distress
occur
transfus
transfus
stop
immedi
treatment
primarili
support
oxygen
ventil
must
maintain
mechan
ventil
implement
necessari
support
evid
use
corticosteroid
antiinflammatori
medic
treatment
trali
trali
typic
resolv
h
caus
perman
pulmonari
damag
although
rare
potenti
sever
complic
blood
product
transfus
although
trali
consid
pediatr
patient
onset
acut
pulmonari
diseas
within
h
follow
transfus
clinician
rememb
condit
may
mimic
trali
diagnosi
acut
intravascular
volum
overload
taco
transfusionassoci
circulatori
overload
consid
child
underli
cardiac
insuffici
hemolyt
transfus
reaction
anaphylaxi
due
transfus
igacontain
product
recipi
iga
defici
may
also
produc
pulmonari
manifest
sever
diagnos
specif
pediatr
hematologyoncolog
popul
may
confus
trali
includ
acut
chest
syndrom
transfus
patient
sickl
cell
anemia
diffus
alveolar
hemorrhag
bone
marrow
recoveri
bone
marrow
transplant
patient
acut
respiratori
distress
occur
granulocyt
transfus
five
percent
platelet
transfus
associ
transfus
reaction
sixti
percent
febril
nonhemolyt
reaction
sinc
platelet
unit
contain
rbc
incid
hemolyt
reaction
follow
platelet
transfus
low
febril
andor
allerg
reaction
follow
platelet
transfus
uncommon
patient
histori
allerg
respons
follow
platelet
transfus
commonli
premed
acetaminophen
andor
diphenhydramin
efficaci
practic
demonstr
literatur
prestorag
leukoreduct
platelet
wash
found
reduc
incid
allerg
reaction
platelet
transfus
advent
univers
leukoreduct
blood
product
unit
state
incid
febril
nonhemolyt
transfus
reaction
decreas
allerg
reaction
becom
common
type
transfus
reaction
bacteri
infect
transmit
platelet
product
divid
two
categori
aris
contamin
store
platelet
product
occur
occult
donor
infect
caus
septic
platelet
transfus
reaction
sptr
store
platelet
product
carri
high
risk
bacteri
contamin
provid
excel
growth
media
bacteria
store
day
bacteri
contamin
occur
everi
unit
platelet
transfusionassoci
bacteri
sepsi
occur
onefourth
onesixth
contamin
platelet
transfus
current
platelet
product
routin
cultur
order
identifi
bacteri
contamin
therebi
reduc
infect
transmiss
attempt
elimin
bacteri
contamin
platelet
product
includ
use
ultraviolet
light
psoralen
method
kill
bacteria
also
virus
white
blood
cell
septic
platelet
transfus
reaction
sptr
attribut
contamin
platelet
unit
donor
skin
flora
asymptomat
bacteremia
donor
sptr
approxim
incid
transfus
mortal
declin
sptr
sinc
adopt
singl
donor
platelet
transfus
sptr
occur
five
time
often
patient
receiv
platelet
concentr
compar
receiv
singl
donor
platelet
increas
donor
exposur
number
phlebotomi
necessari
obtain
pool
platelet
concentr
like
contribut
higher
risk
bacteri
contamin
pool
concentr
sinc
aid
epidem
late
heighten
awar
public
concern
regard
spread
infecti
diseas
transfus
blood
product
american
red
cross
respond
implement
stringent
donor
histori
screen
improv
donor
test
approach
dramat
reduc
blood
product
relat
transmiss
infecti
diseas
recent
develop
implement
molecular
test
polymeras
chain
reaction
pcr
base
nucleic
acid
test
nat
greatli
increas
sensit
infecti
agent
identif
reduc
window
period
period
time
donor
potenti
infecti
neg
serolog
test
exist
window
period
prevent
complet
identif
infect
blood
product
either
serolog
molecular
screen
test
recent
develop
implement
molecular
test
pcr
base
nat
greatli
increas
sensit
infecti
agent
identif
reduc
window
period
howev
window
period
prevent
complet
identif
infect
blood
product
either
serolog
molecular
screen
test
american
red
cross
implement
pcr
nucleic
acid
test
nat
human
immunodefici
viru
hiv
blood
center
perform
nat
assay
hiv
minipool
donor
per
pool
center
perform
singledonor
nat
associ
greater
cost
increas
detect
sensit
hiv
rna
copiesml
implement
minipool
nat
estim
risk
transfusiontransmit
hiv
window
period
day
hepat
b
viru
hbv
detect
difficult
due
transient
natur
hbsag
detect
plasma
current
donor
screen
perform
test
hbsag
antihbc
serolog
obtain
donor
histori
nucleic
acid
test
hbv
develop
implement
unit
state
europ
cost
effect
yet
determin
risk
transfusiontransmit
hbv
estim
window
period
day
pcrbase
nat
test
hepat
c
viru
hcv
implement
approach
reduc
hcv
window
period
day
current
transfusiontransmit
risk
hcv
hepat
e
chronic
phase
virus
transmit
acut
virem
phase
identifi
donor
screen
therefor
specif
serolog
molecular
screen
assay
use
cytomegaloviru
cmv
herp
viru
transmit
leukocyt
therefor
associ
cellular
blood
product
transfus
immunosuppress
patient
risk
acquir
transfusionrel
system
cmv
infect
cmv
signific
caus
mortal
hematopoiet
stem
cell
transplant
patient
transfus
cmvseroneg
blood
product
cmvneg
patient
filtrat
cellular
blood
product
thirdgener
leukocytereduct
filter
found
prevent
cmv
transmiss
debat
exist
whether
cmvseronegatiav
blood
compon
superior
filter
leukoreduc
compon
prevent
transfusiontransmit
cmv
institut
leukoreduc
blood
product
use
cmvseroneg
blood
product
unavail
institut
filter
leukoreduc
blood
product
use
immunocompromis
bone
marrow
transplant
patient
season
flaviviru
west
nile
viru
transmit
mosquito
case
includ
death
report
unit
state
pcr
nat
introduc
west
nile
viru
current
test
perform
region
feder
drug
agenc
approv
nat
viral
genom
expect
shortli
estim
viru
may
present
blood
donor
endem
area
adult
tcell
lymphomaleukemia
atll
peripher
tcell
neoplasm
associ
infect
human
tlymphotroph
viru
type
htlvi
patient
primarili
adult
antibodi
htlvi
viru
endem
island
southern
japan
caribbean
basin
jamaica
trinidad
africa
southeastern
portion
unit
state
viru
may
transmit
sexual
contact
breast
milk
blood
product
current
test
human
tcell
leukemia
viru
htlv
iii
serolog
base
transfusiontransmit
htlviii
estim
occur
transfus
day
window
period
mani
infecti
agent
potenti
transmit
blood
product
transfus
avail
specif
serolog
molecular
test
mani
agent
lack
circumst
posit
donor
histori
lead
defer
reli
upon
prevent
transmiss
sever
acut
respiratori
syndrom
sar
first
identifi
guangdong
provinc
china
novemb
exact
pathogenesi
unknown
sar
thought
result
mutat
coronaviru
paramyxoviru
sar
isol
blood
infect
patient
unknown
whether
transmit
transfus
fda
publish
recommend
donor
suitabl
prevent
transfusiontransmit
sar
donor
defer
week
follow
possibl
exposur
sar
travel
sarsaffect
commun
parvoviru
potenti
transmiss
blood
product
transfus
parvoviru
associ
ill
rare
clinic
signific
except
pregnant
women
caus
hydrou
fetali
hemolyt
anemia
caus
aplast
crisi
immunocompromis
person
estim
parvoviru
viremia
present
approxim
donor
yet
rare
report
transmiss
plasmaderiv
blood
product
specif
donor
test
parvoviru
exist
nanofiltr
andor
heat
inactiv
plasma
product
current
undertaken
prevent
transmiss
spirochet
treponema
pallidum
caus
syphili
transmit
sexual
contact
blood
transfus
case
transfusiontransmit
syphili
report
sinc
serolog
screen
donor
use
autom
treponemalbas
test
continu
mandatori
unit
state
malaria
also
transmit
blood
stream
unit
state
current
fdaapprov
serolog
test
screen
blood
donor
malaria
prevent
transfusiontransmit
malaria
accomplish
donor
deferr
base
travel
histori
despit
case
transfusiontransmit
malaria
occur
year
unit
state
incid
unit
outbreak
variant
creutzfeldtjacob
diseas
vcjd
prion
link
bovin
spongiform
encephalopathi
occur
unit
kingdom
uk
rais
question
whether
vcjd
transmit
human
via
blood
transfus
answer
remain
unknown
unit
state
blood
donor
defer
spent
month
unit
kingdom
spent
month
northern
europ
time
period
live
year
total
europ
receiv
blood
transfus
unit
kingdom
recent
concern
bioterror
rais
question
whether
orthopoxvirus
smallpox
vaccinia
monkeypox
transmit
blood
transfus
last
natur
case
smallpox
occur
somalia
fdaapprov
serolog
studi
screen
orthopoxvirus
unit
state
research
regard
ongo
prematur
infant
receiv
rbc
transfus
varieti
clinic
condit
associ
anemia
respiratori
diseas
apnea
tachycardia
poor
weight
gain
infant
whose
birth
weight
g
receiv
rbc
transfus
neonat
intens
care
unit
nicu
physiolog
anemia
inadequ
bone
marrow
respons
low
level
erythropoietin
poor
nutrit
statu
iron
defici
shorter
rbc
life
span
frequent
blood
sampl
contribut
anemia
blood
group
incompat
hemoglobinopathi
andor
sepsi
present
may
compound
anemia
associ
prematur
red
cell
transfus
practic
vari
greatli
among
intens
care
unit
across
unit
state
inform
regard
neonat
respons
rbc
transfus
lack
evid
base
transfus
guidelin
exist
expert
opinion
primarili
driven
transfus
practic
transfus
recommend
neonat
publish
earli
american
associ
blood
bank
british
committe
standard
haematolog
canadian
pediatr
societi
bodi
support
maintain
hemoglobin
gdl
infant
sever
cardiac
pulmonari
diseas
hemoglobin
gdl
anemia
prematur
compromis
oxygen
deliveri
refer
tabl
detail
neonat
rbc
transfus
recommend
recommend
maintain
hemoglobin
gdl
infant
sever
cardiac
pulmonari
diseas
hemoglobin
gdl
anemia
prematur
compromis
oxygen
deliveri
effort
limit
donor
exposur
transfus
given
small
aliquot
singl
dedic
rbc
unit
dedic
life
span
unit
red
cell
preserv
mannitol
glucos
sodium
chlorid
phosphat
adenin
manipul
order
lengthen
unit
storag
durat
day
previous
describ
prolong
storag
increas
potassium
adenin
mannitol
content
solut
load
magnitud
may
lead
osmot
diuresi
alter
cerebr
microcircul
renal
toxic
small
infant
therefor
altern
rbc
preserv
develop
use
neonat
ml
mannitol
ml
adenin
mg
per
ml
adenin
mannitol
safe
small
volum
mlkg
transfus
neonat
studi
examin
transfus
threshold
children
congenit
heart
diseas
either
pre
postpalli
repar
surgic
procedur
optim
hemoglobin
concentr
children
remain
unknown
subgroup
analysi
patient
tripicu
studi
congenit
heart
diseas
follow
cardiac
surgeri
found
similar
result
treat
restrict
versu
liber
transfus
strategi
appear
children
undergo
biventricular
repair
adequ
hemostasi
achiev
toler
anemia
like
noncardiac
counterpart
howev
children
singl
ventricl
physiolog
mix
cardiac
lesion
caus
cyanosi
exclud
analysi
children
cyanot
cardiac
lesion
secondari
intracardiac
right
left
shunt
chronic
hypoxia
promot
increas
erythropoiesi
maintain
tissu
oxygen
deliveri
postop
children
manag
histor
goal
maintain
higher
hemoglobin
concentr
order
ensur
adequ
tissu
oxygen
deliveri
practic
question
risk
rbc
transfus
increasingli
recogn
adult
pediatr
studi
found
independ
associ
increas
number
rbc
transfus
wors
clinic
outcom
follow
cardiac
surgeri
cardiopulmonari
bypass
addit
overcorrect
avoid
sinc
polycythemia
may
actual
decreas
oxygen
deliveri
polycythemia
may
result
sludg
red
cell
mass
capillari
level
therebi
imped
blood
flow
distal
tissu
prospect
studi
explor
rbc
transfus
strategi
children
singl
ventricl
physiolog
undergo
palli
procedur
focus
infant
children
undergo
bidirect
glenn
fontan
procedur
children
manag
restrict
transfus
strategi
appear
differ
maintain
higher
hemoglobin
level
larger
prospect
studi
includ
neonat
undergo
stage
palliat
need
anemia
cyanot
children
prevent
overcorrect
polycythemia
may
actual
decreas
oxygen
deliveri
sludg
red
cell
mass
capillari
level
imped
blood
flow
distal
tissu
patient
congenit
cardiac
diseas
often
associ
chromosom
abnorm
includ
chromosom
delet
di
georg
syndrom
thu
may
increas
risk
tlymphocyt
deficit
consequ
standard
practic
transfus
popul
filter
irradi
blood
product
two
prbc
unit
prepar
blood
bank
congenit
cardiac
pediatr
patient
requir
cardiopulmonari
bypass
one
unit
fresh
prbc
unit
day
old
poststorag
wash
use
first
prime
bypass
circuit
residu
volum
avail
addit
transfus
requir
ffp
given
routin
cardiopulmonari
bypass
use
pump
prime
second
prbc
unit
irradi
leukoreduc
patient
maintain
filter
irradi
protocol
remaind
hospit
genet
profil
known
cardiopulmonari
bypass
balanc
bleed
thrombosi
derang
thrombocytopenia
result
platelet
consumpt
hemodilut
addit
platelet
render
dysfunct
secondari
hypothermia
follow
activ
releas
mediat
process
travers
bypass
circuit
promot
thrombosi
heparin
fibrinolyt
agent
use
intraop
level
monitor
activ
clot
time
act
also
concomit
risk
bleed
secondari
hemodilut
coagul
protein
cytokinedriven
inflammatori
respons
bypass
circuit
individu
physiolog
degre
cyanosi
postop
hemodynam
instabl
may
contribut
coagulopathi
experienc
children
thrombosi
surgic
graft
artifici
valv
conduit
often
incompat
life
therefor
infus
procoagul
blood
product
use
care
consider
associ
risk
benefit
ecmo
bypass
circuit
channel
blood
oxygen
use
mechan
pump
system
venou
blood
typic
right
atrial
venou
cannula
drain
patient
travel
membran
oxygen
nonpulsatil
roller
pump
return
oxygen
rewarm
blood
patient
via
arteri
venou
cannula
much
like
cardiopulmonari
bypass
maintain
balanc
hemorrhag
complic
circuit
thrombosi
remain
challeng
provid
ecmo
support
patient
ecmo
maintain
heparin
infus
prevent
clot
circuit
activ
clot
time
act
follow
close
goal
despit
anticoagul
heparin
infus
care
replac
coagul
protein
ffp
cryoprecipit
essenti
bypass
circuit
incit
consumpt
coagulopathi
predict
intracrani
hemorrhag
intracrani
hemorrhag
occur
children
ecmo
despit
care
attent
coagul
paramet
common
reason
cessat
treatment
ecmo
reli
upon
use
larg
number
rbc
ffp
platelet
unit
well
care
attent
correct
electrolyt
imbal
may
aris
follow
larg
volum
transfus
hypocalcemia
hyperkalemia
protocol
wash
rbc
unit
given
ecmo
prevent
hyperkalemia
secondari
larg
volum
rbc
transfus
one
earli
studi
estim
approxim
ml
prbc
ml
ffp
two
unit
platelet
transfus
day
neonat
ecmo
studi
shown
benefit
keep
hematocrit
typic
platelet
given
daili
maintain
platelet
count
ffp
cryoprecipit
given
maintain
normal
coagul
protein
associ
renal
diseas
bleed
well
recogn
renal
failur
often
complic
mucocutan
bleed
secondari
impair
hemostasi
use
hemodialysi
periton
dialysi
greatli
decreas
occurr
hemorrhag
complic
clinician
must
remain
awar
hemorrhag
tendenc
urem
patient
hemostat
defect
associ
renal
failur
multifactori
alter
platelet
metabol
vascular
smooth
muscl
endotheli
cell
abnorm
interact
platelet
vessel
wall
found
urem
patient
manag
bleed
urem
patient
includ
increas
von
willebrand
factor
vwf
improv
platelet
dysfunct
histor
use
cryoprecipit
indic
replac
intraven
ddavp
stimul
releas
factor
viii
vwf
endotheli
cell
regard
use
prbc
current
practic
adjust
dialysi
transfus
patient
renal
failur
maintain
hematocrit
recombin
human
erythropoietin
therapi
standard
treatment
anemia
renal
insuffici
use
gener
decreas
number
rbc
transfus
describ
previous
concentr
extracellular
potassium
increas
rbc
storag
durat
increas
renal
failur
patient
requir
rbc
transfus
receiv
blood
less
day
old
prevent
hyperkalemia
blood
unavail
older
blood
wash
immedi
prior
transfus
reduc
potassium
content
patient
classic
hemophilia
hemophilia
insuffici
factor
viii
level
factor
viii
fviii
concentr
therefor
prefer
replac
modal
patient
indic
fviii
infus
children
form
hemophilia
includ
prepar
invas
surgic
procedur
bleed
prophylaxi
prevent
joint
diseas
children
sever
hemophilia
often
receiv
routin
infus
primari
secondari
prevent
bleed
episod
medic
scientif
advisori
council
nation
hemophilia
foundat
recommend
recombin
fviii
firstlin
treatment
patient
plasmaderiv
viral
inactiv
fviii
concentr
also
avail
patient
hemophilia
b
christma
diseas
insuffici
factor
ix
level
fix
fix
prefer
replac
patient
three
type
fix
avail
recombin
fix
prefer
plasmaderiv
fix
prothrombin
complex
concentr
use
treatment
acut
bleed
prophylaxi
factor
viii
factor
ix
defici
sever
bleed
specif
factor
replac
unavail
ffp
given
anemia
quit
common
patient
malign
origin
multifactori
ineffect
suppress
erythropoiesi
secondari
chronic
diseas
marrow
infiltr
myelosuppress
therapi
peripher
destruct
alloimmun
andor
autoimmun
hemolysi
hemorrhag
secondari
acquir
coagulopathi
thrombocytopenia
anatom
lesion
surgic
procedur
transfus
therapi
patient
complic
persist
cytopenia
immunosuppress
group
use
hematopoiet
growth
factor
decreas
need
transfus
institut
patient
malign
place
blood
bank
protocol
consist
irradi
filter
leukoreduc
blood
product
institut
cmvneg
blood
product
util
cmv
serostatu
individu
known
hematopoiet
stem
cell
transplant
hsct
patient
receiv
myeloabl
therapi
particularli
suscept
bleed
complic
hsct
solid
organ
transplant
recipi
immunosuppress
risk
persist
cytopenia
infect
transfusionassoci
infecti
immunolog
complic
immunosuppress
oncolog
transplant
patient
risk
develop
tagvhd
describ
previous
critic
ill
patient
endogen
erythopoietin
level
low
despit
presenc
anemia
howev
research
demonstr
bone
marrow
icu
patient
extrem
respons
exogen
erythropoietin
consequ
postul
administ
exogen
erythropoietin
patient
would
reduc
anemia
necess
transfus
support
main
drawback
use
erythropoietin
therapi
critic
ill
patient
length
time
administr
result
marrow
respons
week
fact
recent
multicent
studi
demonstr
widespread
use
erythropoietin
would
littl
impact
transfus
requir
children
admit
picu
difficult
determin
prospect
picu
patient
extend
length
stay
requir
multipl
rbc
transfus
would
therefor
benefit
erythropoietin
therapi
use
erythropoietin
blood
conserv
therapi
patient
chronic
anemia
ie
secondari
chronic
renal
failur
cancer
etc
well
support
varieti
agent
avail
decreas
bleed
promot
hemostasi
decreas
number
requir
blood
product
transfus
agent
use
increas
concentr
clot
factor
includ
desmopressin
acet
ddavp
estrogen
recombin
factor
viia
vitamin
k
agent
increas
platelet
concentr
activ
includ
recombin
thrombopoietin
recombin
human
antifibrinolyt
includ
transexam
acid
aminocapro
acid
aprotinin
aprotinin
pull
market
secondari
increas
risk
complic
death
hemostat
sealant
dress
also
avail
review
mechan
action
clinic
indic
agent
beyond
scope
chapter
howev
intensivist
awar
agent
exist
may
great
benefit
patient
certain
situat
understand
role
blood
product
manag
critic
ill
patient
extrem
import
blood
product
transfus
exceedingli
common
like
increas
medic
advanc
care
critic
ill
patient
continu
decis
administ
blood
product
must
base
clear
understand
benefit
risk
transfus
made
context
clinic
condit
patient
paramount
import
clinician
familiar
type
blood
product
avail
indic
use
associ
potenti
risk
morn
round
medic
student
suggest
transfus
year
old
patient
idiopath
cardiomyopathi
sinc
hemoglobin
gdl
tachycard
heart
rate
beat
per
minut
blood
pressur
mm
hg
central
venou
pressur
mm
hg
correct
respons
suggest
ano
transfus
hemoglobin
gdlbno
transfus
cardiomyopathi
risk
congest
heart
failurecno
transfus
normotensivedy
transfus
hemoglobin
gdl
cardiomyopathyey
transfus
hemoglobin
gdl
symptomat
ten
year
old
kg
girl
relaps
leukemia
develop
pallor
tachycardia
beat
per
minut
found
hemoglobin
gdl
histori
doxorubicininduc
cardiac
dysfunct
current
left
ventricular
eject
fraction
appropri
dose
durat
pack
red
blood
cell
transfus
mlkg
mlkg
mlkg
hoursdtwo
unit
houretwo
unit
hour
year
old
male
multipl
trauma
develop
symptomat
anemia
prior
administ
pack
red
blood
cell
transfus
child
parent
ask
risk
hiv
transmiss
answer
risk
milliond
million
million
transfus
relat
acut
lung
injuri
best
defin
aacut
onset
chest
pain
within
h
transfus
hypoxemia
mm
hg
bilater
infiltr
chest
radiographi
absenc
left
heart
failurebacut
onset
chest
pain
within
h
transfus
hypoxemia
mm
hg
bilater
infiltr
chest
radiographi
absenc
left
heart
failurecacut
onset
pulmonari
insuffici
within
h
transfus
hypoxemia
mm
hg
bilater
infiltr
chest
radiographi
absenc
left
heart
failuredacut
onset
pulmonari
insuffici
within
h
transfus
hypoxemia
mm
hg
bilater
infiltr
chest
radiographi
absenc
left
heart
failureeacut
onset
pulmonari
insuffici
within
h
transfus
hypoxemia
mm
hg
hypercarbia
mm
hg
bilater
infiltr
chest
radiographi
absenc
left
heart
failur
correct
statement
regard
anemia
red
blood
cell
transfus
amaintain
hemoglobin
level
gdl
critic
ill
children
appropri
therapeut
target
reduc
icu
morbidityboxygen
deliveri
transfus
red
blood
cell
compar
nativ
red
blood
cell
consist
increas
tissu
oxygen
availabilitycpack
red
blood
cell
produc
remov
plasma
cellular
compon
red
blood
cellsdth
abil
heart
increas
cardiac
output
coronari
arteri
blood
flow
respons
sever
anemia
symptomat
patient
underli
cardiovascular
diseas
benefit
red
blood
cell
transfusionewhol
blood
accept
altern
pack
red
blood
cell
transfus
infant
cyanot
heart
diseas
storag
techniqu
lengthen
rbc
lifespan
may
result
detriment
physiolog
chang
includ
adeplet
result
decreas
oxygen
affin
decreas
oxygenhemoglobin
bindingbincreas
result
decreas
oxygen
affin
decreas
oxygenhemoglobin
bindingcincreas
endogen
antioxid
result
damag
cytoskelet
protein
membran
phospholipidsdmorpholog
chang
includ
loss
normal
biconcav
disc
shape
ultim
lead
schistocyt
formationemorpholog
chang
includ
loss
normal
biconcav
disc
shape
ultim
lead
spherocyt
format
year
old
girl
acut
lymphocyt
leukemia
picu
recov
sepsi
extub
hemodynam
support
current
cell
count
white
blood
cell
count
hemoglobin
gdl
platelet
ptptt
inr
within
normal
limit
ooz
around
broviac
cathet
transfus
platelet
order
correct
statement
regard
impend
transfus
aon
unit
platelet
typic
rais
platelet
count
approxim
apheresi
allow
multipl
unit
platelet
collect
singl
donor
therebi
reduc
risk
alloimmunizationcunlik
pack
red
cell
transfus
platelet
transfus
produc
transfusionrel
allerg
reactionsdrefriger
platelet
allow
safe
serial
transfus
unitespleen
sequestr
transfus
platelet
rare
occur
caus
poor
respons
platelet
transfus
eceddeb
